Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression re...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-12-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/1/27 |
| id |
doaj-abbe28130fde49a59d779ebc0ebecc7a |
|---|---|
| record_format |
Article |
| spelling |
doaj-abbe28130fde49a59d779ebc0ebecc7a2021-09-20T10:10:29ZengMDPI AGCurrent Oncology1198-00521718-77292021-12-01282725225910.3390/curroncol28010027Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?Warren Fingrut0Wendy Davis1Eric McGinnis2Karen Dallas3Khaled Ramadan4Hayley Merkeley5Heather Leitch6Yasser Abou Mourad7Ryan D. Cassaday8Camilla Ross9Chantal Léger10Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaDepartment of Medicine, University of Washington, Seattle, WA 98195, USAFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaFaculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z4, CanadaSalvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO.https://www.mdpi.com/1718-7729/28/1/27inotuzumab ozogamicincd22acute lymphoblastic leukemiaflow cytometryimmunotherapy |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Warren Fingrut Wendy Davis Eric McGinnis Karen Dallas Khaled Ramadan Hayley Merkeley Heather Leitch Yasser Abou Mourad Ryan D. Cassaday Camilla Ross Chantal Léger |
| spellingShingle |
Warren Fingrut Wendy Davis Eric McGinnis Karen Dallas Khaled Ramadan Hayley Merkeley Heather Leitch Yasser Abou Mourad Ryan D. Cassaday Camilla Ross Chantal Léger Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? Current Oncology inotuzumab ozogamicin cd22 acute lymphoblastic leukemia flow cytometry immunotherapy |
| author_facet |
Warren Fingrut Wendy Davis Eric McGinnis Karen Dallas Khaled Ramadan Hayley Merkeley Heather Leitch Yasser Abou Mourad Ryan D. Cassaday Camilla Ross Chantal Léger |
| author_sort |
Warren Fingrut |
| title |
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? |
| title_short |
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? |
| title_full |
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? |
| title_fullStr |
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? |
| title_full_unstemmed |
Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient? |
| title_sort |
reevaluating patient eligibility for inotuzumab ozogamicin based on cd22 expression: is dim expression sufficient? |
| publisher |
MDPI AG |
| series |
Current Oncology |
| issn |
1198-0052 1718-7729 |
| publishDate |
2021-12-01 |
| description |
Salvage options for patients with relapsed B-cell acute lymphoblastic leukemia (B-ALL) include inotuzumab ozogamicin (InO), a recombinant, humanized anti-CD22 monoclonal antibody conjugated to the cytotoxic antibiotic calicheamicin. However, the benefit of InO in patients with dim CD22 expression remains unclear. We present a case of a patient with B-ALL who responded to InO despite only dim surface expression of CD22 by flow cytometry, achieving a survival benefit concordant with that reported in the literature and maintaining a good quality of life as a transfusion-independent outpatient. Our observation has broad relevance to clinicians who manage patients with B-ALL who are candidates for InO. |
| topic |
inotuzumab ozogamicin cd22 acute lymphoblastic leukemia flow cytometry immunotherapy |
| url |
https://www.mdpi.com/1718-7729/28/1/27 |
| work_keys_str_mv |
AT warrenfingrut reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT wendydavis reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT ericmcginnis reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT karendallas reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT khaledramadan reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT hayleymerkeley reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT heatherleitch reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT yasseraboumourad reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT ryandcassaday reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT camillaross reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient AT chantalleger reevaluatingpatienteligibilityforinotuzumabozogamicinbasedoncd22expressionisdimexpressionsufficient |
| _version_ |
1717374618176585728 |